Neogen [NEOG] vs Charles River [CRL] Detailed Stock Comparison

Neogen Corporation

NASDAQ
Loading...

Charles River Laboratories International, Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Neogen Corporation wins in 7 metrics, Charles River Laboratories International, Inc. wins in 12 metrics, with 0 ties. Charles River Laboratories International, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Neogen Corporation Charles River Laboratories International, Inc. Better
P/E Ratio (TTM) 865.00 681.33 Charles River Laboratories International, Inc.
Price-to-Book Ratio 0.98 2.61 Neogen Corporation
Debt-to-Equity Ratio 37.82 81.95 Neogen Corporation
PEG Ratio 14.79 20.54 Neogen Corporation
EV/EBITDA 33.05 12.23 Charles River Laboratories International, Inc.
Profit Margin (TTM) -69.94% -3.60% Charles River Laboratories International, Inc.
Operating Margin (TTM) -1.56% 4.51% Charles River Laboratories International, Inc.
EBITDA Margin (TTM) N/A 4.51% N/A
Return on Equity -25.57% -4.23% Charles River Laboratories International, Inc.
Return on Assets (TTM) -0.61% 4.24% Charles River Laboratories International, Inc.
Free Cash Flow (TTM) $-46.35M $518.49M Charles River Laboratories International, Inc.
1-Year Return 53.07% 33.24% Neogen Corporation
Price-to-Sales Ratio (TTM) 2.36 2.06 Charles River Laboratories International, Inc.
Enterprise Value $2.69B $10.72B Charles River Laboratories International, Inc.
EV/Revenue Ratio 3.09 2.67 Charles River Laboratories International, Inc.
Gross Profit Margin (TTM) 46.88% 31.15% Neogen Corporation
Revenue per Share (TTM) $4 $81 Charles River Laboratories International, Inc.
Earnings per Share (Diluted) $-2.80 $-2.90 Neogen Corporation
Beta (Stock Volatility) 1.97 1.62 Charles River Laboratories International, Inc.
Short % of Float 6.18% 10.71% Neogen Corporation

Neogen Corporation vs Charles River Laboratories International, Inc. Stock Performance Analysis

Loading Price Chart...

NEOG
CRL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Neogen Corporation0.69%-4.27%-3.74%-21.52%47.80%25.00%
Charles River Laboratories International, Inc.2.91%11.47%1.39%-2.18%-0.03%-13.69%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Neogen Corporation53.07%-51.54%-80.17%-53.16%-15.62%296.90%
Charles River Laboratories International, Inc.33.24%-9.95%-46.35%110.50%383.44%347.52%

Performance & Financial Health Analysis: Neogen Corporation vs Charles River Laboratories International, Inc.

MetricNEOGCRL
Market Information
Market Cap i$2.04B$8.28B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i3,110,790761,885
90 Day Avg. Volume i2,601,313865,618
Last Close$8.81$179.87
52 Week Range$4.53 - $11.43$132.65 - $228.88
% from 52W High-22.92%-21.41%
All-Time High$48.85 (Apr 26, 2021)$460.21 (Sep 20, 2021)
% from All-Time High-81.97%-60.92%
Growth Metrics
Quarterly Revenue Growth-0.04%-0.01%
Quarterly Earnings Growth-0.04%-0.01%
Financial Health
Profit Margin (TTM) i-0.70%-0.04%
Operating Margin (TTM) i-0.02%0.05%
Return on Equity (TTM) i-0.26%-0.04%
Debt to Equity (MRQ) i37.8281.95
Cash & Liquidity
Book Value per Share (MRQ)$9.66$64.30
Cash per Share (MRQ)$0.74$4.34
Operating Cash Flow (TTM) i$69.44M$737.65M
Levered Free Cash Flow (TTM) i$19.47M$572.38M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Neogen Corporation vs Charles River Laboratories International, Inc.

MetricNEOG (Apr 24, 2026)CRL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i865.00681.33
Forward P/E i32.1113.59
PEG Ratio i14.7920.54
Price to Sales (TTM) i2.362.06
Price to Book (MRQ) i0.982.61
Market Capitalization
Market Capitalization i$2.04B$8.28B
Enterprise Value i$2.69B$10.72B
Enterprise Value Metrics
Enterprise to Revenue i3.092.67
Enterprise to EBITDA i33.0512.23
Risk & Other Metrics
Beta i1.971.62
Book Value per Share (MRQ) i$9.66$64.30

Financial Statements Comparison: Neogen Corporation vs Charles River Laboratories International, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNEOG (2025)CRL (2025)
Revenue/Sales i894.66M4.02B
Cost of Goods Sold i473.29M2.69B
COGS % of Revenue i52.9%67.0%
Gross Profit i421.38M1.32B
Gross Margin i47.1%33.0%
Research & Development i21.09MN/A
Operating Income (EBIT) i-1.68M401.14M
Operating Margin i-0.2%10.0%
EBITDA i123.51M786.81M
EBITDA Margin i13.8%19.6%
Pre-Tax Income i-1.13B-99.50M
Pre-Tax Income % of Revenue i-126.7%-2.5%
Income Tax i-41.07M42.66M
Income Tax % of Revenue i-4.6%1.1%
Net Income (Profit) i-1.09B-142.16M
Profit Margin i-122.1%-3.5%

Balance Sheet & Liquidity Metrics

MetricNEOG (2025)CRL (2025)
Cash & Equivalents i129.00M213.77M
Total Current Assets i576.94M1.45B
Total Current Assets % of Revenue i64.5%36.0%
Total Current Liabilities i174.01M1.12B
Total Current Liabilities % of Revenue i19.4%27.9%
Long-Term Debt i874.81M2.57B
Long-Term Debt % of Revenue i97.8%64.0%
Total Shareholders Equity i2.07B3.21B
Retained Earnings i-536.42M1.39B
Retained Earnings % of Revenue i-60.0%34.6%
Property, Plant & Equipment i17.15M361.42M

Cash Flow Statement Comparison

MetricNEOG (2025)CRL (2025)
Operating Cash Flow i-1.01B194.22M
Operating Cash Flow % of Revenue i-113.0%4.8%
Capital Expenditures i-99.52MN/A
Free Cash Flow i-46.35M518.49M
FCF Margin i-5.2%12.9%
Debt Repayment i-550.32M-1.35B
Common Stock Repurchase iN/A-360.67M

Short Interest & Institutional Ownership Analysis

MetricNEOGCRL
Shares Short i10.07M4.59M
Short Ratio i4.095.18
Short % of Float i6.18%10.71%
Shares Outstanding i217.67M49.22M
Float Shares i216.51M48.66M
% Held by Insiders i0.94%0.85%
% Held by Institutions i106.92%110.31%
% Held by Public i-7.86%-11.16%

Dividend Analysis & Yield Comparison: Neogen Corporation vs Charles River Laboratories International, Inc.

MetricNEOGCRL
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A